Parallax by Ankur Kalra

In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery. SGLT2 inhibitors are proving to be the blockbuster drug of this decade: Sukh summarises and compares the learnings from DAPA-HF, Emperor-Reduced, and Emperor-Preserved. Next, Sukh highlights the data from SOLOIST-WHF that showed sotagliflozin to have beneficial effects on CV outcomes among patients with type 2 diabetes and HF. Additionally, they discuss how findings on finerenone (FIGARO-DKD) will shape the field. Sukh talks about the semaglutide and the STEP studies, an injectable medication that further expends cardiologist knowledge beyond their speciality. Ankur and Sukh reflect on how the advancement of this field shaped their own practices. 2021 was a busy year for cardiac surgery trials: Sukh and Ankur review the most pertinent data from the AVATAR randomised study presented at AHA 2021. Su